Baird analyst Joel Beatty lowered the firm’s price target on Arrowhead to $58 from $60 and keeps an Outperform rating on the shares. The analyst said he maintained his rating but admitted the earnings call did leave us feeling less near-term conviction as management confirmed its HBV partnership is likely to end soon.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARWR: